Dendritic cells: On the move from bench to bedside
- PMID: 11433329
- DOI: 10.1038/89863
Dendritic cells: On the move from bench to bedside
Abstract
As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
